Separation

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

Retrieved on: 
Friday, March 22, 2024
Research, Separation, Biotechnology, Regeneration, AgeX Therapeutics, Finance, Exchange, Accounting standard, Insurance, Bank statement, ASC, Therapy, Patent, Private law, Consultant, Ageing

ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights.

Key Points: 
  • ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights.
  • The Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of AgeX common stock on February 1, 2024.
  • As of December 31, 2023, AgeX owed Juvenescence Limited $4.5 million in principal and origination fees on account of loans extended to AgeX.
  • Operating expenses for the full year 2023 were $10.1 million as compared with $7.0 million in the same period of 2022.

Worthington Enterprises Reports Third Quarter Fiscal 2024 Results

Retrieved on: 
Wednesday, March 20, 2024
Consumer, Separation, Conference, Builders hardware, Use, Final good, WAVE, Video game

Income tax expense was $18.5 million in the current year quarter compared to $7.4 million in the prior year quarter.

Key Points: 
  • Income tax expense was $18.5 million in the current year quarter compared to $7.4 million in the prior year quarter.
  • On an adjusted basis, the effective tax rate was 23.1% in the current year quarter compared to 20.9% in the prior year quarter.
  • The Company ended the third quarter of fiscal 2024 with cash of $227.3 million.
  • “Worthington Enterprises is operating well as we head into our fourth quarter,” Rose said.

Politan Nominates Two Independent Candidates for Masimo Board

Retrieved on: 
Monday, March 25, 2024
Banking, Professional Services, Finance, Analytical chemistry, Biophysical environment, Health, Lead, Doctor of Philosophy, IP, M&A, Audit committee, Corporate spin-off, Audit, WHEN, WILL, Science, MASI, Stryker Corporation, Laboratory, Dentsply Sirona, Compensated emancipation, Common stock, Financial management, Knowledge, Broadcom Inc., Acquisition, Security (finance), Senior, INC, Avient Corporation, Annual general meeting, Separation, WALL, MIT, Common, Hope College, Stanford University, National academy, Government, COGS, Management

Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it is nominating two candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”).

Key Points: 
  • Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it is nominating two candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”).
  • Quentin Koffey, Managing Partner and Chief Investment Officer of Politan, and a current director on the Masimo Board, stated:
    “When shareholders overwhelmingly elected Michelle Brennan and me to the Masimo Board last year, we were optimistic we could work productively with the rest of the Board to drive positive change.
  • However, at this stage the Board has been provided zero details, and Politan has serious concerns given the lack of basic governance and oversight we have observed since joining the Board.
  • The participants in the proxy solicitation are Politan, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, Politan Capital NY LLC, Politan Intermediate Ltd., Politan Capital Partners Master Fund LP (“Politan Master Fund”), Politan Capital Partners LP (“Politan LP”), Politan Capital Offshore Partners LP (“Politan Offshore” and collectively with Politan Master Fund and Politan LP, the “Politan Funds”), Quentin Koffey, Matthew Hall, Aaron Kapito, William Jellison and Darlene Solomon (collectively, the “Participants”).

INTERNATIONAL GAME TECHNOLOGY PLC REPORTS FOURTH QUARTER AND FULL YEAR 2023 RESULTS

Retrieved on: 
Tuesday, March 12, 2024
IGT, Online, EUR, Inclusion, Separation, Quarter, Conference, Forecasting, Growth, Sony Pictures Television, Chickasaw Nation, Webcast, ESG, Lottery, Research, Diversity, Sale, Acquisition, News, Table, Human Rights Campaign, Moody's Investors Service, GAAP, Intellectual property, Corporation

LONDON, March 12, 2024 /PRNewswire/ -- International Game Technology PLC ("IGT") (NYSE:IGT) today reported financial results for the fourth quarter and full year ended December 31, 2023. Today, at 8:00 a.m. EDT, management will host a conference call and webcast to present the results; access details are provided below.

Key Points: 
  • All figures presented in this news release are prepared under U.S. GAAP, unless noted otherwise.
  • Adjusted figures exclude the impact of items such as purchase accounting, impairment charges, restructuring expense, foreign exchange, and certain one-time, primarily transaction-related items.
  • Constant currency changes for 2023 are calculated using the same foreign exchange rates as the corresponding 2022 period.
  • As a result, the sum of the components may not equal the total amount reported in millions due to rounding.

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Retrieved on: 
Wednesday, March 6, 2024
Oncology, Health, Infectious Diseases, Technology, Software, Artificial Intelligence, Biotechnology, Assignment, Colliers (company), International, Plan, Record, ATL, Growth, British Virgin Islands, Initial, Entrepreneurship, Void coefficient, Automation, Separation, Bank statement, Form 6-K, Security (finance)

Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”).

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”).
  • The Merger Agreement was approved by Aptorum’s and YOOV’s boards of directors (each board of directors, the “Board”), respectively.
  • The Separation will become effective immediately following completion of the Merger.
  • "This transaction marks a significant milestone for YOOV Group Holding, and we are thrilled about the immense opportunities it brings.

Oragenics, Inc. Announces Leadership Transition

Retrieved on: 
Monday, February 12, 2024
Health, Hospitals, Neurology, Managed Care, Pharmaceutical, Biotechnology, Separation, DSM-IV codes, Separable space, Employment, Management

Ms. Murphy will, however, continue to serve the Company as a member of the Company’s board of directors (the “Board”).

Key Points: 
  • Ms. Murphy will, however, continue to serve the Company as a member of the Company’s board of directors (the “Board”).
  • The Separation Agreement provides Ms. Murphy with the benefits under her employment agreement with the Company for a separation without cause.
  • The Board will provide direction to the Company during this transition in management, with Charlie Pope, the Company’s Chairman of the Board, serving, on an interim basis, as Executive Chairman, effective immediately.
  • In addition, effective February 12, 2024, the Board appointed Michael Redmond, the Company’s President, as the Company’s Interim Principal Executive Officer.

NowVertical Group Comments on Press Release Issued by Daren Trousdell

Retrieved on: 
Friday, January 19, 2024
Norton Rose Fulbright, Sale, Acquisition, Separation, AI

TORONTO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- NowVertical Group Inc. (“NowVertical” or the “Company”) (TSX-V: NOW) (OTCQB: NOWVF), a leading data analytics and AI solutions company, responds to a press release issued by Daren Trousdell, a shareholder of NowVertical and a former officer and director of the Company.

Key Points: 
  • TORONTO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- NowVertical Group Inc. (“NowVertical” or the “Company”) (TSX-V: NOW) (OTCQB: NOWVF), a leading data analytics and AI solutions company, responds to a press release issued by Daren Trousdell, a shareholder of NowVertical and a former officer and director of the Company.
  • In connection with Mr. Trousdell’s resignation as an officer and director of the Company at the end of May 2023, Mr. Trousdell signed a separation agreement (the “Separation Agreement”).
  • Over the last six months, the Company has acted decisively to position NowVertical for sustainable long-term organic and inorganic growth, improving shareholder value.
  • Norton Rose Fulbright Canada LLP is acting as legal counsel to NowVertical.

Global Lithium Market Size Expected to See Strong Growth In Next Few Years Growing to $10.44 Billion In 2028

Retrieved on: 
Thursday, January 11, 2024
Lithium, EVS, Research, Electricity, Deposit, Carbon, Livent, Technical report, Growth, ESM, Gasoline, POSCO, DLE, PALM, Smartphone, MRE, NewCo, Resource, Executive, TSX, Water, National instrument, Port, Partnership, OTCQB, News, Separation, Interim, LAAC, Project, PEA, Q3

The global lithium market size is expected to see strongly grown in the next few years.

Key Points: 
  • The global lithium market size is expected to see strongly grown in the next few years.
  • Major trends in the forecast period include advancements in lithium technologies, solid-state lithium batteries, diversification of lithium sources, integration of lithium in aerospace, and decentralized energy solutions.
  • An increase in smartphone adoption is expected to propel the growth of the lithium market going forward.
  • The report continued: “The increasing demand for electric vehicles is expected to propel the growth of the lithium market going forward.

Saviynt To Demonstrate How Enterprise Identity Cloud Supports Greater Efficiency, Security, and Patient Care at Health-ISAC Summit

Retrieved on: 
Tuesday, November 28, 2023
Data Management, Practice Management, Technology, Health, Security, Health Technology, Other Technology, Software, Hospitals, Internet, Mobile, Wireless, EMR, Separation of duties, Separation, SOD, Physician, Syneos Health, Risk management, JW Marriott Hotels

The #1 convergent identity security solution company will also be demonstrating how it delivers rapid, secure onboarding to external physicians and healthcare professionals.

Key Points: 
  • The #1 convergent identity security solution company will also be demonstrating how it delivers rapid, secure onboarding to external physicians and healthcare professionals.
  • Saviynt has helped healthcare systems around the world focus on patient care, not complex identity security management.
  • “With Saviynt IGA, we’ve become far more flexible and agile,” said Mike Rivett, Principal Solutions Architect at Syneos Health.
  • “As the business makes new requests of us, we can immediately change our flows or ways of doing things.

Envista Holdings Corporation Appoints Three New Members to Leadership Team

Retrieved on: 
Thursday, December 14, 2023
Human resources, Research, NYSE, Senior, AstraZeneca, Bank, Nobel Biocare, Gilead Sciences, Seagen, Kite Pharma, Envista Forensics, Global marketing, Information technology, JPMorgan Chase, M&A, Separation, Capital, Internal communications, Danaher Corporation, NVST, Bank of America, Management, Diagnosis, Cepheid variable, LATAM

Robert Befidi joins Envista from 3M, where he most recently was President of the Separation and Purification Sciences Division, a global filtration technology leader.

Key Points: 
  • Robert Befidi joins Envista from 3M, where he most recently was President of the Separation and Purification Sciences Division, a global filtration technology leader.
  • Suraj Satpathy joins Envista Holdings Corporation from Cepheid, a global diagnostics company under the Danaher Corporation, where he most recently served as the Senior Vice President of Human Resources and Internal Communications.
  • Amir Aghdaei, CEO Envista, is working directly with the Nobel Biocare leadership team to expand the business' capabilities and accelerate growth in 2024 until a permanent successor is named.
  • "Envista and our customers will benefit from the leadership and expertise of Robert, Andrew, and Suraj," said Amir.